Lenalidomide for Refractory Cutaneous Manifestations of Pediatric Systemic Lupus Erythematosus

Lenalidomide was evaluated for its efficacy and safety in treating refractory cutaneous manifestations of pediatric systemic lupus erythematosus through a retrospective chart review of 10 adolescents. The study found that within 6 months, all patients showed complete or near resolution of symptoms, including alopecia and various types of skin lesions. The mean prednisone dose significantly decreased from 23.5 mg to 12.25 mg, and the sedimentation rate also decreased from 29 mm/hour to 17 mm/hour. Lenalidomide was well tolerated, suggesting it is an effective and safe treatment that may reduce the need for prednisone and decrease disfigurement. Further prospective studies were recommended to better understand its role.